Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating Winrevair’s Positive Response

Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating Winrevair’s Positive Response

By, Admin 27 November 2024

Merck announces pivotal phase 3 ZENITH trial evaluating Winrevair meets primary endpoint at interim analysis

Overview

Merck, known as MSD outside of the United States and Canada, announced today positive topline results from the phase 3 ZENITH study evaluating Winrevair (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH, WHO Group 1) functional class (FC) III or IV at high risk of mortality. ZENITH met its primary endpoint of time to first morbidity or mortality event (all-cause death, lung transplantation, or PAH worsening related hospitalization of = 24 hours). In the study, Winrevair demonstrated a statistically significant and clinically meaningful reduction in the risk of morbidity or mortality events compared to placebo, both on top of background PAH therapy. Based on the strength of these results, an independent data monitoring committee has recommended ZENITH be stopped early and all participants be offered the opportunity to receive Winrevair through the SOTERIA open-label extension study. In preliminary assessment, adverse events and serious adverse events were balanced between the treatment groups.

Statement from the Merck Research Laboratories

  • PAH is a serious, progressive disease with a high incidence of morbidity and mortality,” said Dr. Eliav Barr, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. 
  • Based on the primary endpoint demonstrating overwhelming efficacy, all ZENITH study participants will be offered the opportunity to receive Winrevair. These findings are impressive, set a high evidentiary bar for studies of future candidates developed for the treatment of PAH and support the potential of Winrevair to be practice-changing in the management of PAH.

Statement from the University of Michigan

  • The ZENITH trial was designed to evaluate whether the addition of Winrevair, an activin signalling inhibitor, could reduce the risk of death, lung transplantation, or PAH hospitalizations for patients living with advanced PAH,” said Dr. Vallerie McLaughlin, Kim A Eagle MD Endowed Professor of Cardiovascular Medicine and Director, Pulmonary Hypertension Program, University of Michigan in Ann Arbor. 
  • This is the first study in PAH in which the interim analysis led to an early conclusion of the study due to overwhelming efficacy. Winrevair has brought significant optimism to the field, and we thank the investigators and patients for being part of this important study.”

Winrevair: Current Approvals

  • Winrevair is currently approved in the US and 36 countries based on the results from the phase 3 STELLAR trial. 
  • Most recently, in November of this year, Winrevair was submitted for approval in Japan based on the STELLAR trial and results from an open-label phase 3 study in Japanese patients.

The ZENITH Study

  • Results from ZENITH will be presented at an upcoming medical meeting and will be submitted to regulatory authorities.
  • The ZENITH study (NCT04896008) is a global, double-blind, placebo-controlled clinical trial to evaluate Winrevair when added to maximum tolerated background PAH therapy on time to first event of all-cause death, lung transplantation, or PAH worsening related hospitalization of = 24 hours, in participants with WHO FC III or IV PAH at high risk of mortality. 
  • ZENITH study inclusion criteria required Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) Lite 2.0 risk score of =9.

The Study

  • The study enrolled 172 participants, who were randomized in a 1:1 ratio to either Winrevair plus background PAH therapy or placebo plus background PAH therapy. 
  • The primary composite outcome measure is time to first confirmed morbidity or mortality event. 
  • Events are defined as all-cause death, lung transplantation, or PAH worsening-related hospitalization of = 24 hours. 
  • Secondary outcome measures include overall survival, transplant-free survival and several additional measures. 
  • Participants who have completed the ZENITH trial have the opportunity to receive sotatercept as part of the open-label, long-term extension study, SOTERIA (NCT04796337), consistent with that study’s eligibility criteria.

Avout Winrevair

  • Winrevair is FDA-approved for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1) to increase exercise capacity, improve WHO functional class (FC) and reduce the risk of clinical worsening events. 
  • Winrevair is the first activin signaling inhibitor therapy approved to treat PAH. 
  • Winrevair improves the balance between pro-proliferative and anti-proliferative signalling to modulate vascular proliferation. 
  • In preclinical models, Winrevair induced cellular changes that were associated with thinner vessel walls, partial reversal of right ventricular remodelling, and improved haemodynamics.

Winrevair is the subject of a licensing agreement with Bristol Myers Squibb.

About PAH

  • Pulmonary arterial hypertension (PAH) is a rare, progressive and life-threatening blood vessel disorder characterized by the constriction of small pulmonary arteries and elevated blood pressure in the pulmonary circulation. 
  • Approximately 40,000 people in the US are living with PAH. The disease progresses rapidly for many patients. 
  • PAH results in significant strain on the heart, leading to limited physical activity, heart failure and reduced life expectancy. The five-year mortality rate for patients with PAH is approximately 43%.

The Merck

At Merck, known as MSD outside of the United States and Canada, the company is unified around our purpose: It use the power of leading-edge science to save and improve lives around the world.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!